文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

硼中子俘获治疗对既往接受过头颈部放疗的下咽癌/喉癌患者的疗效与安全性

Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation.
PubMed 文献 · Radiother Oncol · 2024-06-14

回顾性分析25例下咽癌和11例喉癌患者,均有头颈部放疗史(中位既往放疗剂量70 Gy),评估硼中子俘获治疗(BNCT)的疗效与安全性。完全缓解率72%,总缓解率84%,1年局部控制率和无进展生存率分别为63.1%和53.7%,中位生存时间15.5个月,2年总生存率79.8%。急性3级不良事件为口腔黏膜炎(6%)、咽黏膜炎(3%)和软组织感染(3%),急性期除高淀粉酶血症外无4-5级不良事件,晚期无3级及以上不良事件。

要点

  • BNCT对既往头颈部放疗后的下咽癌/喉癌完全缓解率72%、总缓解率84%。
  • 1年局部控制率63.1%、无进展生存率53.7%,中位生存时间15.5个月,2年总生存率79.8%。
  • 急性3级不良事件为口腔黏膜炎6%、咽黏膜炎3%、软组织感染3%,无4-5级不良事件(高淀粉酶血症除外),晚期无3级及以上不良事件。

核心结论

  • BNCT可获得良好的肿瘤缓解,同时保留喉部且无严重不良事件。

研究设计与样本

  • 回顾性研究,分析有局部病灶的下咽癌/喉癌患者,包括治疗后复发和第二原发 cases,共25例下咽癌和11例喉癌。

主要发现

  • 全部患者均有头颈部放疗史,中位既往放疗剂量为70 Gy。
  • 完全缓解率为72%,总缓解率为84%,1年局部控制率为63.1%,1年无进展生存率为53.7%。
  • 中位生存时间为15.5个月,2年总生存率为79.8%。
  • 27例完全缓解患者中,11例在中位6.0个月时复发。
  • 急性3级不良事件为口腔黏膜炎(6%)、咽黏膜炎(3%)和软组织感染(3%);急性期除高淀粉酶血症外无4-5级不良事件,晚期无3级及以上不良事件。

关键数值与推荐

  • 完全缓解率72%,总缓解率84%。
  • 1年局部控制率63.1%,1年无进展生存率53.7%。
  • 中位生存时间15.5个月,2年总生存率79.8%。
  • 27例完全缓解患者中11例复发,中位复发时间6.0个月。
  • 急性3级不良事件:口腔黏膜炎6%、咽黏膜炎3%、软组织感染3%;急性期除高淀粉酶血症外无4-5级不良事件,晚期无3级及以上不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patients with hypopharyngeal cancer (HPC)/laryngeal cancer (LCA) with a history of head and neck irradiation are often difficult to treat with conventional radiotherapy. This study aimed to clarify the efficacy and safety of boron neutron capture therapy (BNCT) for HPC/LCA. MATERIALS AND METHODS: In this retrospective study, HPC/LCA with local lesions were analyzed, including both recurrent cases after treatment and second primary cases. The primary endpoints were tumor response and incidence of adverse events (AEs) after BNCT. The secondary endpoints were local control (LC), progression-free survival (PFS), and overall survival (OS). Evaluation of tumor response was terminated when any additional treatment was administered, and only survival data were collected. RESULTS: The analysis included 25 and 11 cases of HPC and LCA, respectively. All had a history of head and neck irradiation, and median dose of prior radiotherapy was 70 Gy. The complete response (CR) rate was 72%, overall response rate was 84%, and the 1-year LC and PFS were 63.1% and 53.7%, respectively. The median survival time was 15.5 months, and the 2-year OS was 79.8%. Of the 27 patients with CR, 11 cases recurred at a median of 6.0 months. The acute G3 AEs were oral mucositis (6%), pharyngeal mucositis (3%), and soft tissue infection (3%). Acutely, there were no G4-5 AEs, except hyperamylasemia, and in the late phase, there were no G3 or higher AEs. CONCLUSION: BNCT can be achieve good tumor response while preserving the larynx without severe AEs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sato M, Hirose K. Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation. Radiother Oncol. 2024. PMID: 38880413. doi:10.1016/j.radonc.2024.110382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。